Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Genome-wide DNA copy number predictors of lapatinib sensitivity in tumor-derived cell lines.

Molecular cancer therapeutics - 1 Apr 2008

Greshock Joel, Cheng Jie, Rusnak David, Martin Anne Marie, Wooster Richard, Gilmer Tona, Lee Kwan, Weber Barbara L, Zaks Tal

Abstract excerpt

A common aim of pharmacogenomic studies that use genome-wide assays on panels of cancers is the unbiased discovery of genomic alterations that are associated with clinical outcome and drug response. Previous studies of lapatinib, a selective dual-kinase inhibitor of epidermal growth factor receptor (EGFR) and HER2 tyrosine kinases, have shown predictable relationships between the activity of these target genes...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Agents
Share to Gene Dosage

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Gene Expression Regulation, Neoplastic

Share to Genome, Human

Share to Lapatinib

Share to Quinazolines

Share to ROC Curve

Share to Tumor Cells, Cultured

Source

Identifiers

PMID: 18413807
DOI: 10.1158/1535-7163.MCT-07-2072

Genes

EGFR

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Genome-wide DNA copy number predictors of lapatinib sensitivity in tumor-derived cell lines.PMID 18413807Read ↗

Integrative proteo-genomic profiling uncovers key biomarkers of lapatinib resistance in HER2-positive breast cancerSemantic proximity Read ↗

Copy number alterations that predict metastatic capability of human breast cancer.Semantic proximity Read ↗

The Prospective role of lapatinib as an adjuvant therapy in prevalent cancers: Insights from in silico analysis targeting EGFR and HER2Semantic proximity Read ↗

Integrating data on DNA copy number with gene expression levels and drug sensitivities in the NCI-60 cell line panel.Semantic proximity Read ↗

Copy Number Amplification of DNA Damage Repair Pathways Potentiates Therapeutic Resistance in CancerSemantic proximity Read ↗

Clinical response to a lapatinib-based therapy for a Li-Fraumeni syndrome patient with a novel HER2V659E mutation.Semantic proximity Read ↗

A Phase II Biomarker-Embedded Study of Lapatinib plus Capecitabine as First-line Therapy in Patients with Advanced or Metastatic Gastric Cancer.Semantic proximity Read ↗

A novel treatment strategy for lapatinib resistance in a subset of HER2-amplified gastric cancerSemantic proximity Read ↗

High-level copy number gains of established and potential drug target genes in gastric cancer as a lead for treatment development and selection.Semantic proximity Read ↗

The Cyclin D1 (CCND1) A870G polymorphism predicts clinical outcome to lapatinib and capecitabine in HER2-positive metastatic breast cancer.Semantic proximity Read ↗

Estimating copy number using next-generation sequencing to determine ERBB2 amplification statusSemantic proximity Read ↗

Phosphatidylinositol 3-kinase hyperactivation results in lapatinib resistance that is reversed by the mTOR/phosphatidylinositol 3-kinase inhibitor NVP-BEZ235.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.